Evidence map›Paper›PMID 40079268›Full record

ArticleJournal of biochemical and molecular toxicology2025

Development of 1,2,3-Triazolopyridazinone Derivatives as Potential Caspase 3 and Apoptosis Inducers: Design, Synthesis and Anticancer Activity Studies.

Guler Yagiz Erdemir, Ali Kuruçay, Burhan Ates, Aliye Altundas

Abstract read
In one paragraph

Article in Journal of biochemical and molecular toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Guler Yagiz ErdemirDepartment of Chemistry, Faculty of Science, Gazi University, Ankara, Türkiye.
Ali KuruçayDepartment of Chemistry, Faculty of Science and Arts, Inonu University, Malatya, Türkiye.
Burhan AtesDepartment of Chemistry, Faculty of Science and Arts, Inonu University, Malatya, Türkiye.
Aliye AltundasDepartment of Chemistry, Faculty of Science, Gazi University, Ankara, Türkiye.ORCID http://orcid.org/0000-0003-4616-4513

Funding

Financial support was provided by the Türkiye Bilimsel ve Teknolojik Arastirma Kurumu.
6 · The paper itself

Abstract

Herein, the synthesis, anticancer activity and apoptotic pathways of 1,2,3-triazolopyridazinones compounds, which are similar to DNA bases not previously found in the literature have been investigated. To achieve this goal, it is designed the hybrid molecules combining triazole and pyridazinone/pyridazithione structures, bearing a lipophilic group (benzyl/phenyl) at the one position and benzene with electron withdrawing or donating groups at five positions, with high pharmacophoric properties on the same scaffold structure. The representative compounds in this series 5a, 5c, 6a and 8c exhibited higher anticancer activity than other compounds and cisplatin control against breast (MCF-7) and lung (A549) cell lines. These compounds were less toxic when tested against the noncancerous L929 cell line. In addition, the apoptotic effect mechanisms of these compounds were confirmed by AO/EB staining and caspase 3 activity results. These findings indicate that some derivatives of these compounds could be effective therapeutic agents for the treatment of cancer disease with an apoptosis-promoting.

Indexed as

Antineoplastic AgentsApoptosisCaspase 3PyridazinesTriazolesAnimalsCell LineDrug DesignHumansMiceAntineoplastic AgentsCaspase 3PyridazinesTriazoles1,2,3‐triazoleanticancerapoptosiscaspase 3 activitypyridazinonetriazolopyridazinone

Identifiers

PMID40079268
PMCPMC11905200

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.